BAAR, Switzerland and MOUNTAIN VIEW, Calif. – atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company’s Board of Directors. With over thirty years of experience, including specific expertise bringing game-changing technologies to market, Mr....
Latest News
BOTHELL, Wash— Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a...
BOTHELL, Wash. — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration, today announced a planned poster presentation at the upcoming American Academy of Neurology (AAN) 2024 Annual Meeting, to be held April 13 – 18,...
JIANGSU, China — Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of ABP-745,...
BUFFALO, NY – A new research paper was published in Oncotarget, entitled “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.” Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the DNA damage response (DDR)...
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug Administration (FDA) has agreed to the expansion of the company’s ongoing Phase 1 / 2 LIGHTHOUSE study of...
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201...
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis...
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ATSN-101, the company’s investigational gene therapy being evaluated in...
A cross-sectional study found that caregivers of patients with ovarian cancer were experiencing symptoms of depression and anxiety which were affected by attachment avoidance. These findings were published in Current Oncology. Caregivers are an important component of successful cancer treatment, as they ensure treatment adherence as well as provide much needed...